Sun Tao, Zhang Weihua, Chen Lei, Ren Yanqiao, Liu Yiming, Zheng Chuansheng
Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, China.
J Cancer. 2022 Jan 24;13(4):1282-1288. doi: 10.7150/jca.67523. eCollection 2022.
Previous studies reported that drug-eluting beads transarterial chemoembolization (DEB-TACE) with CalliSpheres is effective and safe to treat hepatocellular carcinoma patients and metastatic liver cancer patients, however few studies reported its clinical application in intrahepatic cholangiocarcinoma (ICC) patients. Therefore, this study aimed to compare the efficacy between DEB-TACE versus conventional transarterial chemoembolization (cTACE) in unresectable ICC patients. Between January 2016 and June 2020, 89 patients with unresectable ICC were retrospectively analyzed, and enrolled into DEB-TACE group (N=40) and cTACE group (N=49) based on the transarterial treatment. Treatment response was assessed according to modified Response Evaluation Criteria in Solid Tumors (mRECIST). Time to progression (TTP) and overall survival (OS) were analyzed by using the Kaplan-Meier curve. Factors affecting OS and TTP were determined by Cox's proportional hazards regression model. DEB-TACE group showed higher DCR (87.5% vs. 65.3%, =0.011), while similar ORR (67.5% vs. 57.1%, =0.317) compared to cTACE group. Furthermore, DEB-TACE group had longer OS (median 10 months vs 6 months, =0.006), while similar TTP compared to cTACE group (median 4 months vs 2 months, =0.098). After adjustment by multivariant Cox's regression, DEB-TACE (versus cTACE) independently correlated with longer OS (=0.031). Further subgroup analyses displayed that OS was prolonged in DEB-TACE group compared to cTACE group in patients with multiple tumors (=0.032) and patients with no lymph node metastasis (=0.023). Apart from abdominal pain, no difference of adverse events between the two groups was observed. There was no difference in liver function (Bilirubin, Albumin, Prothrombin time) before and after treatment (4 weeks) in both groups. In patients with unresectable ICC, DEB-TACE significantly improved the OS when compared with cTACE and was well tolerated.
既往研究报道,使用载药微球经动脉化疗栓塞术(DEB-TACE)治疗肝细胞癌患者和转移性肝癌患者有效且安全,然而鲜有研究报道其在肝内胆管癌(ICC)患者中的临床应用。因此,本研究旨在比较DEB-TACE与传统经动脉化疗栓塞术(cTACE)在不可切除ICC患者中的疗效。2016年1月至2020年6月,对89例不可切除ICC患者进行回顾性分析,并根据经动脉治疗情况将其纳入DEB-TACE组(N=40)和cTACE组(N=49)。根据改良实体瘤疗效评价标准(mRECIST)评估治疗反应。采用Kaplan-Meier曲线分析疾病进展时间(TTP)和总生存期(OS)。通过Cox比例风险回归模型确定影响OS和TTP的因素。与cTACE组相比,DEB-TACE组的疾病控制率更高(87.5%对65.3%,P=0.011),而客观缓解率相似(67.5%对57.1%,P=0.317)。此外,DEB-TACE组的OS更长(中位数10个月对6个月,P=0.006),而与cTACE组的TTP相似(中位数4个月对2个月,P=0.098)。经多变量Cox回归调整后,DEB-TACE(与cTACE相比)与更长的OS独立相关(P=0.031)。进一步的亚组分析显示,在多发肿瘤患者(P=0.032)和无淋巴结转移患者(P=0.023)中,DEB-TACE组的OS比cTACE组延长。除腹痛外,两组不良事件无差异。两组治疗前(4周)和治疗后肝功能(胆红素、白蛋白、凝血酶原时间)无差异。在不可切除的ICC患者中,与cTACE相比,DEB-TACE显著改善了OS,且耐受性良好。